The Lasting Impact Of The Pandemic On Pharmacovigilance

By Barry Mulchrone & Annette Williams

With COVID-19 again on the rise, the global pandemic continues to impact daily lives and company operations. The pharma sector has seen significant disruption, including how it ensures effective safety monitoring of COVID-19 vaccines and medicines following expedited development and accelerated approvals. Regulators, healthcare professionals, and pharma manufacturers are challenged with real-time reporting and monitoring of emerging safety data for these newly developed vaccines and treatments.